Journal Articles
Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay
H. Barton Grossman; Edward Messing; Mark Soloway; Kevin Tomera; Giora Katz; Yitzhak Berger; Yu Shen JAMA. 293:810-816, 2005.

A study comparing various noninvasive methods of detecting bladder cancer in urine.
Saad, A., Hanbury, D.C., McNicholas, T.A., Boustead, G.B., Morgan, S., Woodman, A.C. British Journal of Urology. 89:369-373, 2002.

Value of Urinary NMP22 in Patients with Renal Cell Carcinoma.
Ozer, G., Altinel, M., Kocak, B., Yaziciogl, A., Gonenc, F. Urology, 60:593-597, 2002.

A comparison of urinary NMP22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer.
Poulakis, V., Witzsch, U., DeVries, R., Altmannsberger, H-M., Manyak, M.J., Becht, E. British Journal of Urology. 88:692-701, 2001.

Screening and Monitoring for Bladder Cancer: Refining the Use of NMP22.
Ponsky, L., Sharma, S., Pandrangi, L., Kedia, S., Nelson, D., Agarwal, A., Zippe, C. Journal of Urology. 166. 2001

Urinary NMP22 and Renal Cell Carcinoma.
Huang, S., Rhee, E., Patel, H., Park, E., Kawsick, J. Urology, 55:227-230, 2000.

The Role of Nuclear Matrix Proteins in Cancer Diagnosis.
Watkins, B.A., Hartshorn, C. Amer Clinl Lab, 18:28-29, 1999.

Evaluation of Urinary Level of NMP22 as a Diagnostic Marker for Stage pTa-pT1 Bladder Cancer: Comparison with Urinary Cytology and BTA Test.
Del Nero, A., Esposito, N., Curro, A., Biasoni, D., Montanari, E., Mangiarotti, B., Trinchieri, A., Zanetti, G., Serrago, MP., Pisani E. Eur Urol, 35:93-97, 1999.

NMP22 is a Sensitive, Cost-Effective Test in Patients at Risk for Bladder Cancer.
Zippe, C., Pandrangi, L., Agarwal, A. J Urol, 161:62-65, 1999.

Comparison of Screening Methods in the Detection of Bladder Cancer.
Ramakumar, S., Bhuiyan, J., Besse, JA., Roberts, SG., Wollan, PC., Blute, ML., O’Kane, D.J. J Urol, 161(2):388-394, 1999.

Exclusion Criteria Enhance the Specificity and Positive Predictive Value of NMP22 and BTA Stat.
Sharma, S., Zippe, C., Pandrangi, L., Nelson, D., Agarwal, A. J Urol, 162(1):53-57, 1999.

The Mechanism and Clinical Applications of the NMP22 Tumor Marker Immunoassay: A Review.
Sawczuk, I.S., Lee, B. Amer Clin Lab, 18(3):24-26, 1999.

Comparison of Nuclear Matrix Protein 22 and Bladder Tumor Antigen in Urine of Patients with Bladder Cancer.
Abbate, I., D’Introno, A., Cardo, G., Marano, A., Addabbo, L., Musci, MD., Pagliarulo, A., Correale, M., Quaranta, M. Anticancer Res, 18(5B):3803-3805, 1998.

Urinary NMP22 and Karyometry in the Diagnosis and Follow-Up of Patients with Superficial Bladder Cancer.
Witjes, J.A., van der Poel, H.G., van Balken, M.R., Debruyne, F.M.J., Schalken, J.A. Eur Urol, 33:387-391, 1998.

Sensitivity and Specificity of NMP-22, Telomerase, and BTA in the Detection of Human Bladder Cancer.
Landman, J., Chang, Y., Kavalier, E., Droller, MJ., Liu, BC-S. Urology 52(3):398-402, 1998.

Evaluation of NMP22 in the Detection of Transitional Cell Carcinoma of the Bladder.
Stampfer, D.A., Carpinito, G.A., Rodriguez-Villanueva, J., Willsey, L.W., Dinney, C.P., Grossman, H.B., Fritsche, H.A., McDougal, W.S. J Urology, 159:394-398, 1998.

Sensitivity and Specificity of NMP22, Telmoerase and BTA in the Detection of Human Bladder Cancer.
Landman, J., Chang, Y., Kavaler, E., Droller, M., Liu, B. Urology, 52: 398-402, 1998.

Clinical Evaluation of NMP22 in Urine as a Novel Marker for Urothelial Cancer.
Miyanaga, N., European Urology, 31:163-168. 1997

Comparison of Urine Collection Methods for Evaluating Urinary Nuclear Matrix Protein, NMP22, as a Tumor Marker.
Chen, Y-T., Hayden, C.L., Marchand, KJ., Makuch, R.W. J Urology, 158:1899-1901, 1997.

Clinical Evaluation of Nuclear Matrix Protein 22 (NMP22) in Urine as a Novel Marker for Urothelial Cancer.
Miyanaga, N., Akaza, H., Ishikawa, S., Mikinobu, O., Noguchi, R., Kawai, K., Koiso, K., Kobayashi, M., Koyama, A., Takahashi, T. Eur Urology 31:163-168, 1997.

Evaluation of Urinary NMP22 (Nuclear Matrix Protein 22) as a Diagnostic Marker for Urothelial Cancer - Screening for Urothelial Cancer in Patients with Microscopic Hematuria.
Akaza, H., Miyanaga, N., Tsukamoto, T., Ishikawa, S., Noguchi, R., Ohtani, M., Kawabe, K., Kubota, Y., Fujita, K., Obata, K., Hirao, Y., Kotake, T., Ohmori, H., Kumazawa, J., Koiso, K. Jpn J Cancer Chemotherapy 24(7):837-842, 1997.

Urinary Nuclear Matrix Protein as a Marker for Transitional Cell Carcinoma of the Urinary Tract.
Carpinito, G.A., Stadler, W.M., Soloway, M.S., Briggman, J.V., Chodak, G.W., Church, P.A., Lamm, D.L., Lange, P., Messing, E., Pasciak, R.M., Reservitz, G.B., Ross, R.N., Rukstalis, D.B., Sarosdy, M.F., Soloway, M.S., Thiel, R.P., Volgelzang, N., Hayden, C.L. J Urology 156:1280-1285, 1996.

Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract following Surgical Treatment.
Soloway, M.S., Briggman, J.V., Carpinito, G.A., Chodak, G.W., Church, P.A., Lamm, D.L., Lange, P., Messing, E., Pasciak, R.M., Reservitz, G.B., Rukstalis, D.B., Sarosdy, M.F., Stadler, W.M., Thiel, R.P., Hayden, CL. J Urology 156:363-367, 1996.